Drug Royalty Corp. Buys Future Royalty Rights to Arthritis Drug from MGH
 
Toronto-based Drug Royalty Corporation last week said that it has acquired the future right to receive royalties on the sale of the drug Enbrel from the Massachusetts General Hospital.
 
Under the terms of the agreement, Drug Royalty has paid MGH and Enbrel’s faculty inventors a one-time payment of $300 million less accrued royalties for the period from July 1, 2006 to December 31, 2006.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.